New CAR-T therapy targets Hard-to-Treat cancers
NCT ID NCT07181720
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new type of immunotherapy called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, ovarian, and thyroid cancers. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack cancer cells that have a protein called CD70, and infusing them back into the body. The main goals are to check safety and find the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD70-targeted CAR-T cells
- What this could lead to
- If successful, this could provide a new treatment option for patients with advanced solid tumors that have not responded to standard therapies.
- What could go wrong
- This is an early Phase 1 trial with only 90 participants, so safety and effectiveness are not yet proven. CAR-T therapy can cause severe side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC THYROID CARCINOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The 901 Hospital of Joint Logistics Support Force of People Liberation Army
RECRUITINGHefei, Anhui, 230031, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Your Tumor's DNA might predict immunotherapy success
- Can a new PET tracer light up hidden cancers?